Form 8-K - Current report:
SEC Accession No. 0001493152-24-036055
Filing Date
2024-09-12
Accepted
2024-09-12 16:25:28
Documents
24
Period of Report
2024-09-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 56103
2 ex4-1.htm EX-4.1 162446
3 ex5-1.htm EX-5.1 17747
4 ex10-1.htm EX-10.1 672991
5 ex99-1.htm EX-99.1 18649
6 ex99-2.htm EX-99.2 14086
7 ex5-1_001.jpg GRAPHIC 11691
8 ex5-1_002.jpg GRAPHIC 11831
9 ex5-1_003.jpg GRAPHIC 9128
10 ex99-1_001.jpg GRAPHIC 17174
  Complete submission text file 0001493152-24-036055.txt   1426788

Data Files

Seq Description Document Type Size
11 XBRL SCHEMA FILE bctx-20240911.xsd EX-101.SCH 3750
12 XBRL DEFINITION FILE bctx-20240911_def.xml EX-101.DEF 29998
13 XBRL LABEL FILE bctx-20240911_lab.xml EX-101.LAB 36631
14 XBRL PRESENTATION FILE bctx-20240911_pre.xml EX-101.PRE 27021
28 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5668
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 241295254
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)